* Exagen Inc XGN.OQ XGN.O is expected to show a rise in
quarterly revenue when it reports results on August 7.
* The Vista California-based company is expected to report
a
22.0% increase in revenue to $10.937 million from $8.96 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. The company's guidance on May 15 2023,
for the period ended June 30, was for revenue between $10.70
million and $11.20 million.
* Refinitiv's mean analyst estimate for Exagen Inc is for a
loss
of 49 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Exagen Inc
is
$6.5, above its last closing price of $2.46.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.57 -0.56 -0.44 Beat 21.7
Dec. 31 2023 -0.81 -0.78 -0.83 Missed -6.4
Sep. 30 2022 -0.73 -0.73 -0.47 Beat 35.6
Jun. 30 2022 -0.57 -0.57 -0.78 Missed -36.8
Mar. -0.61 -0.61 -0.60 Beat 1.4
31 2022
Dec. 31 2021 -0.44 -0.50 -0.42 Beat 15.4
Sep. 30 2021 -0.47 -0.46 -0.42 Beat 8.7
Jun. 30 2021 -0.47 -0.44 -0.38 Beat 13
This summary was machine generated August 4 at 18:07 GMT. All
figures in US dollars unless otherwise stated